Aortic Dissections after Transcatheter Aortic Valve Replacement

Tyler M Bauer, MD, David Williams, MD, Stanley Chetcuti, MD, P. Michael Grossman, MD, G, Michael Deeb, MD, Himanshu J. Patel, MD, Shinichi Fukuhara, MD

> Department of Cardiac Surgery University of Michigan Ann Arbor, USA



Introduction

- Incidence of Aortic Dissection after TAVR: 0.2 1.9%
 - Based solely on registry studies without granular data
 - No differentiation of type A or B dissection
- Characteristics & Management
 - Poorly understood (only successfully managed case reports published)

Langer NB, et al. Injuries to the Aorta, Aortic Annulus, and Left Ventricle During Transcatheter Aortic Valve Replacement: Management and Outcomes. Circ Cardiovasc Interv. 2017 Jan;10(1):e004735.




Objectives — Aortic Dissections and TAVR

- Describe the incidence, characteristics, management and outcomes of aortic dissections based on our 12-year TAVR experience
- Share lessons learned from this series



Cohort — Aortic Dissections and TAVR



Timing of Diagnosis and Interventions

| | Type A 11 | Type B 4 | | |
|-------------------------------|----------------------------------|---------------------------------------------------------------------------|--|--|
| Intraoperative: | | | | |
| Pre-deployment | TEVAR (n=1) | | | |
| Post-deployment | TEVAR (n=2) Open Repair (n=2) | TEVAR (n=1) Endovascular Reperfusion (n=1) Medical Management (n=1) | | |
| Post Discharge | | | | |
| Less than 3 months | TEVAR (n=1) Open Repair (n=3) | TEVAR (n=1) | | |
| Greater than 3 months | Open Repair (n=2) | | | |
| Department of Cardiac Surgery | | | | |

Demographics — Aortic Dissections and TAVR

| Characteristics | N=15 (%) |
|------------------------------------------|------------------------|
| Age (Years) | 79.5 (IQR 72.3 – 90.5) |
| Female | 6 (40.0%) |
| Diabetes | 3 (20.0%) |
| Frailty | 9 (60.0%) |
| Previous stroke | 3 (20.0%) |
| Coronary artery disease | 7 (46.6%) |
| Chronic kidney disease | 6 (40.0%) |
| Dialysis | 1 (6.7%) |
| Home O2 therapy | 3 (20.0%) |
| STS-PROM (%) | 8.5 (IQR 7.3 – 14.3) |
| Previous cardiovascular surgery | |
| SAVR | 2 (13.3%) |
| Aortic root repair | 2 (13.3%) |
| Ascending and partial aortic arch repair | 1 (6.7%) |
| CABG | 2 (13.3%) |
| Endovascular abdominal aortic repair | 3 (20.0%) |

Characterized by

- High-risk
- Frail
- Multiple comorbidities



Aortic Characteristics: Type A Group (n=11)

| Patient | Age Gender | Aortic risk factors | Associated aortic complications | Intimal tear location | Aortic dissection mechanism | Dx timing (Dx imaging) |
|---------|---------------|---------------------------------------------------------------------------------------------------------------------|-------------------------------------------|-----------------------------------|--------------------------------------------------------|---------------------------------------------------------------|
| 1 | 86 M | h/o ascending IMH Moderately dilated ascending aorta (46 mm) Horizontal aorta | Cerebral malperfusion | STJ (greater curvature) | TAVR valve deployment | Post-deployment (aortography, dampened right radial pressure) |
| 2 | 79 F | Mildly dilated ascending aorta (43 mm) Horizontal aorta Immunosuppression | Cerebral malperfusion, hemopericardium | Mid ascending (greater curvature) | TAVR device delivery system passage | Post-deployment (aortography, dampened right radial pressure) |
| 3 | 71 F | Moderately dilated ascending aorta (45 mm) | None | Root (greater curvature) | TAVR device delivery system passage | Pre-deployment (pre-deployment aortography) |
| 4 | 93 F | Moderately dilated ascending aorta (45 mm) Horizontal aorta | None | STJ (greater curvature) | Distal TAVR stent frame contact to the aorta | 1.5 months post-TAVR (CTA) |
| 5 | 72 M | Mildly dilated ascending aorta (43 mm) Intimal plaque at STJ | Large pseudoaneurysm | STJ (greater curvature) | Distal TAVR stent frame contact to the aorta | Late (CTA) |
| 6 | 85 F | - Horizontal aorta | None | STJ (greater curvature) | Snaring for distal migration | 2 days post-TAVR (CTA) |
| 7 | 25 M | Large aortic root (47 mm)Horizontal aorta | None | STJ (greater curvature) | Repeat deployment and recapturing | Late (CTA) |
| 8 | 71 M | Horizontal aortaElongated aorta | None | STJ (greater curvature) | Repeat deployment and recapturing | 10 days post-TAVR (CTA) |
| 9 | 78 F | Moderately dilated ascending aorta (48 mm) | Cerebral malperfusion | STJ (greater curvature) | Retrograde migration requiring 2 nd TAVR | Late (CTA) |
| 10 | 78 M | Moderately dilated ascending aorta (45 mm) | Rupture Hemopericardium | Root (greater curvature) | TAVR valve deployment | Post-deployment (echo) |
| 11 | 76 M | - Infrarenal aortic aneurysm | None | Root (greater curvature) | Repeat deployment and recapturing | Post-deployment (echo) |

All patients had ascending aortic dilatation/horizontal aorta/Entry tear all located along greater curvature



Interventions and Outcomes: Type A Group (n=11)

| Patient | Management | Dx timing Entry tear location | Procedural success | Outcomes |
|---------|-----------------------------------|------------------------------------------|-------------------------------------|----------------------------------------|
| 1 | TEVAR | Post-TAVR deployment STJ | No (incomplete entry tear coverage) | Death on POD#2 (sudden cardiac arrest) |
| 2 | TEVAR, innominate artery stenting | Post-TAVR deployment Mid ascending | Yes | Death on POD#5 (massive stroke) |
| 3 | TEVAR | Pre-TAVR deployment Root | Yes | Death on POD#5 (sudden cardiac arrest) |
| 4 | TEVAR | Post-TAVR deployment (1.5 months) STJ | No (incomplete entry tear coverage) | Death on POD#18 (palliative care) |
| 5 | Root & ascending repair | Late STJ | Yes | Alive (3 years) |
| 6 | Ascending & hemiarch repair | Post-discharge (2 days) STJ | Yes | Alive (2 years) |
| 7 | Root & ascending repair | Late STJ | Yes | Alive (7 months) |
| 8 | Ascending repair | Post-discharge (10 days) STJ | Yes | Alive (4 months) |
| 9 | Ascending & hemiarch repair | Late STJ | Yes | Alive (4 months) |
| 10 | Root & ascending repair | Post-TAVR deployment Root | Yes | Alive (1 month) |
| 11 | Root & ascending repair | Post-TAVR deployment STJ | Yes | Alive |

TEVAR, thoracic endovascular aortic repair; POD, postoperative day




Lessons Learned: Type A Group

- All had ascending aorta pathology at baseline
- Most patients demonstrated unfavorable features for conservative management (malperfusion, hemopericardium, proximal entry tears)
- Entry tears mostly located at proximal aorta (STJ or more proximal) always along greater curvature
- Presence of TAVR valve and associated proximal landing difficulty (TEVAR-in-TAVR configuration, figures)
- Lack of dedicated CTA to assess TEVAR feasibility for immediate TEVAR management
- Lack of dedicated aortic prosthesis for ascending TEVAR
- Open repair is highly warranted if patients are surgical candidates

kimal tion, ibility ending Complete coverage of entry

Complete coverage of entry tear at STJ (Aortic dissection recognized prior to TAVR implantation)

TAVR-in-TEVAR (n=1)



TEVAR-in-TAVR (n=3)

Rigit

Incomplete coverage of entry tear (entry tear at STJ)



Aortic Characteristics: Type B Group (n=4)

| Pati ent | Age, gender | Aortic risk factors | Associated aortic complications | Intimal tear location | Aortic dissection mechanism | Timing of Dx (imaging) |
|-------------|----------------|-------------------------------------------------------------------------|----------------------------------------------------------------------------|--------------------------|--------------------------------------------------------------------------------------------------------------------|------------------------------------------------|
| 12 | 80 <i>,</i> M | Ascending aortic dilatation (43 mm) | Rapidly growing aneurysm (3.5 cm → 7.4 cm/3months), leg malperfusion | Zone 3 | Intimal tear from embolized & snared TAVR stent frame | 3 months (CTA) |
| 13 | 92, F | Severe aortic calcification | Retrograde type A aortic dissection | Zone 3 | TAVR device delivery system passage | Post-deployment (completion aortography) |
| 14 | 73 <i>,</i> M | Severe aortic tortuosity | Leg malperfusion | Zone 3 | TAVR device delivery system passage | Post-deployment (lack of femoral pulse) |
| 15 | 86, M | Severe aortic tortuosity, ascending aortic aneurysm (55 mm) | Renal malperfusion | Zone 3 | Repetitive TAVR device delivery system passage (aorta too long and the device did not reach the valve) | Pre-deployment (aortography) |



Outcomes: Type B Group (n=4)

| Patient | Management | Procedural success | Outcomes |
|---------|-----------------------------------------------------------------------------------------------------------------------|--------------------|--------------------------------------------------------------------|
| 12 | Zone 1 trans-embolized TAVR TEVAR using laser aortic septotomy | Yes | Alive, positive aortic remodeling (2 years) |
| 13 | Zone 2 TEVAR | Yes | Alive, positive aortic remodeling (4 years) |
| 14 | Endovascular reperfusion using dissection flap fenestration/true lumen & bilateral iliac stenting (No TEVAR) | Yes | Alive for 8 years, died of aortic rupture (known 6 cm aneurysm) |
| 15 | Medical management | N/A | Died of end-organ malperfusion and multi-organ failure |


Both TEVAR cases resulted in positive aortic remodeling




Lessons Learned: Type B Group

• Favorable outcomes with TEVAR

Fenestration & stent alone without TEVAR (Patient#14)



- TEVAR and entry coverage at acute stage may be highly warranted
 - Patient#12 with chronic dissection required a complex TEVAR (Figure below)
 - patient#14 without TEVAR developed large aortic aneurysm (Figure right) and eventually died of rupture





Summary — Aortic Dissections and TAVR

- Underlying aortic pathology (dilated aorta) +/- catheter manipulations associated with implantation difficulty (horizontal aorta) are the main mechanism of aortic dissection.
- Preoperative aorta assessment and avoiding TAVR in patients with such characteristics can make the incidence almost zero (currently 0.6%).
- Open repair is preferred to TEVAR for type A aortic dissection. Immediate TEVAR poses unique challenges (TEVAR-in-TAVR).
- TEVAR for type B aortic dissection may be highly warranted at acute phase.



